Opening Hours : Luni - Vineri, 8:30 - 17:00.
(1)National Cancer Institute, BRCA1 and BRCA2: Cancer Risk and Genetic Testing, reviewed 01/22/2014; (2)Genetics Home Reference, BRCA 1, BRCA 2, reviewed August 2007; (3)Rosen EM1, Fan S, Goldberg ID. BRCA1 and prostate cancer. Cancer Invest. 2001;19(4):396-412. [PubMed Abstract]; (4)Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. Journal of the National Cancer Institute 2002; 94(18):1365–1372.[PubMed Abstract]; (5)Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296(2):185–192.[PubMed Abstract]; (6)Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 2007; 99(23):1811–1814.[PubMed Abstract]; (7)Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of Clinical Oncology 2009; 27(3):433–438.[PubMed Abstract];; (8)Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics 2003; 72(5):1117–1130.[PubMed Abstract]; (9)Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 2007;